Hub: Tech for Good - Page 2
Stories from Hub: Tech for Good come first, newest first, then stories from connected topics (AI Science & Health, Biotech, AI for science, drug discovery, protein design, Healthcare), each labelled with where it comes from. This view is not indexed by search engines.
Latest
Oracle and AstraZeneca to Explore AI for Finding Clinical-Trial Patients
Oracle and AstraZeneca signed a non-binding agreement to explore AI and real-world data to find clinical-trial patients sooner. No terms or dates given.
Endurance Energy Says Seafloor Geothermal Test Made Net-Positive Power
Endurance Energy says its Adélie test plant made net-positive power for 8.7 seconds on an underwater volcano off Oregon. It is a test, not a power plant.
Lilly Taps Metis TechBio’s AI to Steer Medicines to Target Tissues
Metis TechBio will use AI to design tissue-targeted drug carriers for Eli Lilly. Upfront cash is low double-digit millions; milestones run up to $1.1bn.
Johns Hopkins-Led Team Wins Up to $52.1m to Model Protein Misfolding
Johns Hopkins leads an ARPA-H award of up to $52.1m over four years for an open protein-misfolding AI model, starting with Parkinson’s and Ewing sarcoma.
Google Research Puts AI Agents on Wet-Lab Robots for Closed-Loop Design
Google Research: VERID digital twin on PyLabRobot, closed-loop aptamers, nanomolar FAP binders. Authors’ self-published results, not peer-reviewed.
Google Messages Gets an “Enhanced Protection” Mode as Android Adds New Scam Safeguards on a Staggered Rollout
Google Messages gets opt-in Enhanced protection using cloud Gemini, plus Android call-forwarding and screen-share safeguards on a staggered rollout.
Google DeepMind Shows Its Antigravity Agent Finding a New Antimicrobial Peptide Candidate, Which Still Needs Lab Testing
Google DeepMind says its Antigravity agent helped find a new antimicrobial peptide candidate. It is a computational lead now in lab testing.
Sanofi Options First Development Candidate From Its Recursion AI Collaboration
Sanofi has optioned a potential first-in-class oral immunology candidate from Recursion, triggering a $10m milestone. Phase 1 is planned for 2027.
insitro and AstraZeneca Sign AI Collaboration to Hunt Drugs for MASH and Cardiomyopathies
insitro gets $40m upfront and is eligible for up to about $1.46bn in potential milestones in an AstraZeneca AI deal for MASH and heart disease.
Brooklyn DA and FBI Disrupt 112 Servers and 241 Domains Behind a Crypto Scam Targeting Russian Speakers
Brooklyn's DA says his Virtual Currency Unit and the FBI disrupted 112 servers and 241 domains behind a crypto investment scam aimed at Russian speakers.
Latest on TSN
Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.